Senti Biosciences Partners with Celest Therapeutics for Clinical Development of SENTI-301A in China, Stock Skyrockets Over 100%
In a strategic move aimed at advancing cancer treatment in China, Senti Biosciences has entered into a collaboration with Celest Therapeutics (Shanghai) Co Ltd, a